Vafidemstat
Modify Date: 2024-01-09 22:08:54
Vafidemstat structure
|
Common Name | Vafidemstat | ||
|---|---|---|---|---|
| CAS Number | 1357362-02-7 | Molecular Weight | 336.39 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H20N4O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of VafidemstatVafidemstat is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor. |
| Name | Vafidemstat |
|---|
| Description | Vafidemstat is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor. |
|---|---|
| Related Catalog | |
| Target |
LSD1/MAO-B[1] |
| In Vitro | Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease[2]. |
| References |
[2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018. |
| Molecular Formula | C19H20N4O2 |
|---|---|
| Molecular Weight | 336.39 |